Clinical Trial

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT

Name: Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT — clinical trial record (NCT07442513)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation.

Trial Details

NCT Number	NCT07442513
Lead Sponsor	First Affiliated Hospital of Zhejiang University
Conditions	Hematopoietic Stem Cell Transplantation, Thrombocytopenia
Enrollment	404 participants
Start Date	2025-12-16
Primary Completion	2027-10-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-02